A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy

Inclusion Criteria: * Subjects (male or female) from 16 to 80 years of age at Visit 1, both inclusive * Female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method * Subjects having at least 8 partial seizures (according to the 1981 ILAE classification) during the 8-Week Baseline Period with at least 2 partial seizures during each 4-week interval of the Baseline Period * Subjects having at least 2 partial seizures whether or not secondary generalization per month during the 3 months preceding Visit 1 * Subjects uncontrolled while treated by 1 or 2 permitted concomitant antiepileptic drug \[AED\](s). Vagal Nerve Stimulation (VNS) is allowed and will be counted as a concomitant AED Exclusion Criteria: * Subject has history or presence of status epilepticus during the year preceding Visit 1 or during Baseline * Subject is currently treated with levetiracetam * Subject has taken levetiracetam within 90 days prior to Visit 1